These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 16687402)

  • 1. Mutational analysis of the p53 core domain L1 loop.
    Zupnick A; Prives C
    J Biol Chem; 2006 Jul; 281(29):20464-73. PubMed ID: 16687402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
    Cho Y; Gorina S; Jeffrey PD; Pavletich NP
    Science; 1994 Jul; 265(5170):346-55. PubMed ID: 8023157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function.
    Kong XT; Gao H; Stanbridge EJ
    J Biol Chem; 2001 Aug; 276(35):32990-3000. PubMed ID: 11395510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights.
    Merabet A; Houlleberghs H; Maclagan K; Akanho E; Bui TT; Pagano B; Drake AF; Fraternali F; Nikolova PV
    Biochem J; 2010 Mar; 427(2):225-36. PubMed ID: 20113312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of the DNA-binding-induced loop L1 conformational switch in an engineered human p53 protein.
    Emamzadah S; Tropia L; Vincenti I; Falquet B; Halazonetis TD
    J Mol Biol; 2014 Feb; 426(4):936-44. PubMed ID: 24374182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In the quest for stable rescuing mutants of p53: computational mutagenesis of flexible loop L1.
    Pan Y; Ma B; Venkataraghavan RB; Levine AJ; Nussinov R
    Biochemistry; 2005 Feb; 44(5):1423-32. PubMed ID: 15683227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific DNA binding by different classes of human p53 mutants.
    Rolley N; Butcher S; Milner J
    Oncogene; 1995 Aug; 11(4):763-70. PubMed ID: 7651740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors governing loss and rescue of DNA binding upon single and double mutations in the p53 core domain.
    Wright JD; Noskov SY; Lim C
    Nucleic Acids Res; 2002 Apr; 30(7):1563-74. PubMed ID: 11917017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.
    Calhoun S; Daggett V
    Biochemistry; 2011 Jun; 50(23):5345-53. PubMed ID: 21561095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based rescue of common tumor-derived p53 mutants.
    Wieczorek AM; Waterman JL; Waterman MJ; Halazonetis TD
    Nat Med; 1996 Oct; 2(10):1143-6. PubMed ID: 8837616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity.
    Petty TJ; Emamzadah S; Costantino L; Petkova I; Stavridi ES; Saven JG; Vauthey E; Halazonetis TD
    EMBO J; 2011 Jun; 30(11):2167-76. PubMed ID: 21522129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1, and 53BP2.
    Thukral SK; Blain GC; Chang KK; Fields S
    Mol Cell Biol; 1994 Dec; 14(12):8315-21. PubMed ID: 7969167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discrimination of DNA binding sites by mutant p53 proteins.
    Thukral SK; Lu Y; Blain GC; Harvey TS; Jacobsen VL
    Mol Cell Biol; 1995 Sep; 15(9):5196-202. PubMed ID: 7651437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2.
    Gorina S; Pavletich NP
    Science; 1996 Nov; 274(5289):1001-5. PubMed ID: 8875926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
    Forrester K; Lupold SE; Ott VL; Chay CH; Band V; Wang XW; Harris CC
    Oncogene; 1995 Jun; 10(11):2103-11. PubMed ID: 7784055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
    Di Como CJ; Prives C
    Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library.
    Shiraishi K; Kato S; Han SY; Liu W; Otsuka K; Sakayori M; Ishida T; Takeda M; Kanamaru R; Ohuchi N; Ishioka C
    J Biol Chem; 2004 Jan; 279(1):348-55. PubMed ID: 14559903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region.
    Srinivasan R; Maxwell SA
    Oncogene; 1996 Jan; 12(1):193-200. PubMed ID: 8552392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.